You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

 

4885 Results
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Curative
May 2019
Regimen
Cancer Type:
Hematologic, 
Rare Diseases
Intent: Curative
May 2019
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
New Drug Funding Program
    Trastuzumab (Biosimilar) - Second Line - Metastatic Breast Cancer
Apr 2023
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
New Drug Funding Program
    Bendamustine - Relapsed_Refractory - Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
May 2019
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL), 
Leukemia - Acute Myeloid (AML), 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Palliative, Curative
Jan 2018
Regimen
Intent: Palliative
Apr 2023
Regimen
Intent: Palliative
Jul 2023
Regimen
Cancer Type:
Lung, 
Non-Small Cell, 
Small Cell
Intent: Adjuvant, Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
Nov 2023
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Adjuvant
Aug 2020
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Adjuvant
Jun 2019

Pages